BNTX (BNTX) Stock Price & Analysis
BNTX (BNTX) fell 2.97% to USD 89.33 as of July 25, 2026 at 01:44 UTC, according to Nexqual real-time market data.
BNTX last closed at USD 92.06; the session ranged USD 88.92–92.16 on volume of 886,017 shares. Market capitalization is $22.59B, with a 52-week range of USD 79.52–124 (NMS). Source: Nexqual, July 25, 2026 at 01:44 UTC.
Key Statistics (as of July 25, 2026 at 01:44 UTC)
| Price | USD 89.33 |
|---|---|
| Change | ▼ 2.97% (down) |
| Previous Close | USD 92.06 |
| Open | USD 92.16 |
| Day Range | USD 88.92 – 92.16 |
| 52-Week Range | USD 79.52 – 124 |
| Volume | 886,017 shares |
| Market Cap | $22.59B |
| Exchange | NMS |
Technical Analysis (BNTX)
Nexqual's technical model rates BNTX "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 01:44 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 43.72 (neutral) |
| vs SMA50 | Below (USD 91.15) |
| MACD | -0.19 (negative) |
Analyst Ratings (BNTX)
Wall Street analysts rate BNTX "Buy" based on 20 analysts, with a mean price target of USD 121.58 (range USD 75.62–153.88), per Nexqual as of July 25, 2026 at 01:44 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 20 |
| Mean Target | USD 121.58 |
| High Target | USD 153.88 |
| Low Target | USD 75.62 |
| Buy / Hold / Sell | 15 / 5 / 0 |
Earnings (BNTX)
| Next Earnings Date | 2026-08-04 |
|---|---|
| EPS Estimate | USD -2.08 |
| Revenue Estimate | $155.71M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.95 vs est -1.92 ▼ miss |
| 2025-12-31 | USD -0.33 vs est -0.25 ▼ miss |
| 2025-09-30 | USD -0.12 vs est 0.1 ▼ miss |
| 2025-06-30 | USD -1.6 vs est -1.41 ▼ miss |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Financials & Fundamentals (BNTX)
| Total Revenue | $2.81B |
|---|---|
| Revenue Growth (YoY) | -35.40% |
| Gross Margin | +78.65% |
| Operating Margin | -576.63% |
| Profit Margin | -44.64% |
| ROE | -6.66% |
| Debt / Equity | 1.62 |
| Current Ratio | 8.8 |
| Total Cash | $13.71B |
| Total Debt | $302.80M |
| Free Cash Flow | $-428.11M |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Financial Health Score (BNTX)
Nexqual rates BNTX's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 01:44 UTC.
| Growth | Mixed — Revenue +4.3% YoY (annual), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $13.7B cash vs $303M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$428M, burning cash |
| Efficiency | Critical — ROE -7%, ROA -4.2% |
Ownership (BNTX)
| Insider Ownership | +57.13% |
|---|---|
| Institutional Ownership | +20.46% |
| Shares Outstanding | 252.88M |
| Float | 110.10M |
| Short % of Float | +3.40% |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Leadership (BNTX)
BNTX is led by Ugur Sahin (age 60), Co-Founder, CEO & Chair of the Management Board, per Nexqual as of July 25, 2026 at 01:44 UTC.
| Co-Founder, CEO & Chair of the Management Board | Ugur Sahin (age 60) |
|---|---|
| CFO & Member of Management Board | Ramon Zapata-Gomez (age 51) |
| MD, COO & Member of Management Board | Sierk Pötting (age 52) |
| Senior Vice President of Global Financial Reporting & Accounting | Lisa Birringer |
| Vice President of Strategy & Investor Relations | Douglas Maffei |
Major Backers & Investors (BNTX)
Notable institutional backers of BNTX include T. Rowe Price, Dodge & Cox Inc., FMR, LLC, according to Nexqual as of July 25, 2026 at 01:44 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 3.62% |
| Dodge & Cox Inc. | 2.45% |
| FMR, LLC | 2.26% |
| Primecap Management Company | 1.5% |
| Fidelity | 1.49% |
| Flossbach von Storch SE | 1.46% |
| BNP Paribas Financial Markets | 0.65% |
| Temasek Holdings (Private) Ltd | 0.6% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 0.9% |
| Vanguard Group | 0.87% |
Source: Nexqual, July 25, 2026 at 01:44 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRNA | Moderna, Inc. | USD 54.07 | ▼ 6.89% |
| NVAX | Novavax, Inc. | USD 7.46 | ▼ 5.69% |
| AZN | AstraZeneca PLC | USD 169.26 | ▼ 0.28% |
| INO | Inovio Pharmaceuticals, Inc. | USD 0.97 | ▼ 8.49% |
| VXRT | Vaxart, Inc. | USD 0.5 | ▲ 3.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 01:44 UTC. This page is informational and not investment advice.